Equities research analysts expect Check Cap Ltd (NASDAQ:CHEK) to post earnings of ($0.47) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Check Cap’s earnings, with estimates ranging from ($0.48) to ($0.45). Check Cap posted earnings of ($1.52) per share in the same quarter last year, which would indicate a positive year over year growth rate of 69.1%. The business is expected to report its next earnings report on Thursday, May 16th.
According to Zacks, analysts expect that Check Cap will report full year earnings of ($1.70) per share for the current fiscal year, with EPS estimates ranging from ($2.06) to ($1.34). For the next year, analysts expect that the firm will report earnings of ($1.70) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Check Cap.
Check Cap (NASDAQ:CHEK) last issued its quarterly earnings results on Thursday, March 28th. The medical research company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.04).
CHEK has been the subject of a number of research reports. Zacks Investment Research raised shares of Check Cap from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Monday, March 4th. Dougherty & Co initiated coverage on shares of Check Cap in a report on Tuesday, February 5th. They issued a “buy” rating and a $6.00 price target for the company.
A hedge fund recently bought a new stake in Check Cap stock. Dimensional Fund Advisors LP acquired a new stake in Check Cap Ltd (NASDAQ:CHEK) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 35,131 shares of the medical research company’s stock, valued at approximately $141,000. Dimensional Fund Advisors LP owned approximately 2.20% of Check Cap as of its most recent filing with the SEC.
Check Cap stock traded up $0.09 during mid-day trading on Friday, reaching $2.55. The company had a trading volume of 52,629 shares, compared to its average volume of 332,836. Check Cap has a 52 week low of $1.62 and a 52 week high of $19.78. The company has a market cap of $4.09 million and a PE ratio of -0.98.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Get a free copy of the Zacks research report on Check Cap (CHEK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.